The Indian pharmaceutical industry is once again issuing news. Indian Pharma manufacturers recently met Union Commerce Minister Piyush Goyal. The need was straightforward but of great significance since they want the US government to leave the generic medicines out of its inquiry on pharmaceutical imports.
This inquiry that is being conducted under Section 232 is supposed to examine the influence of the imports of medicines on the national security of the United States. However, Indian firms fear that inclusion of generic drugs will cause great trouble to patients as well as the industry.
Why Generic Medicines Are Important
India is often called the “Pharmacy of the World” because it produces affordable and reliable generic medicines for people all around the globe. In fact, almost 40% of generic drugs used in the US come from India.
Generic medicines are cheaper versions of branded drugs. They have the same quality and effect but cost less. This makes them very important for patients who cannot afford costly branded medicines.
If the US probe includes generics, it could:
-
Break the supply chain.
-
Increase the price of medicines in the US.
-
Hurt millions of American patients who depend on Indian generics.
This is why Indian drugmakers are asking for generics to be kept out of the investigation.
Trade Talks Between India and the US
The timing of this request is important. India and the US are currently talking about trade deals. But there is also tension because of the possibility of new US tariffs. If tariffs or restrictions are put on generic medicine, it will hurt not just India but also the US, where patients need these low-cost drugs.
Over the years, India and the US have benefited from each other in the pharma sector. India provides affordable medicines, while the US helps with technology and raw materials. A sudden restriction would damage this strong relationship.
Problems Already Facing Indian Pharma
Indian pharma companies are already facing several difficulties:
-
They import many raw materials (APIs) from China, and costs are rising.
-
The USFDA has strict rules and inspections, which companies must follow.
-
Global competition is increasing, pushing down prices.
-
Trade policy changes are creating uncertainty.
If the US adds more hurdles by including generics in the Section 232 probe, things will become even tougher.
Monopoly Medicines vs Generics
This debate also brings up the difference between monopoly medicines and generics. Monopoly medicines are those sold by one company under patent protection. They are often expensive because no other company can make them for a few years. On the other hand, generics are cheaper copies available once the patent expires.
India has strong positions in both areas. It is known as a monopoly medicine company in India and at the same time, it is the largest supplier of generic drugs to the world. If generics are treated the same way as monopoly medicines in this probe, it will create confusion and unfair restrictions.
Role of Contract Manufacturing in India
Another big strength of Indian pharma is contract manufacturing. Many global companies get their medicines made in Indian factories because of low cost, skilled workers, and high-quality production. A pharma contract manufacturing company in India can handle bulk production, packaging, and even R&D for foreign brands.
This has made India a major part of the global medicine supply chain. If the US decides to impose restrictions, it will not only hurt Indian firms but also US companies who rely on Indian contract manufacturers for their supplies.
What Could Happen Next?
There are two possible outcomes from the US probe:
-
If Generics Are Included:
-
Supplies of cheap medicines will reduce.
-
Prices in the US will go up.
-
Indian companies will lose revenue.
-
Relations between India and the US may weaken.
-
-
If Generics Are Exempted:
-
Patients in the US will continue to get affordable medicines.
-
Trade ties between India and the US will remain strong.
-
Indian drugmakers will continue to play a global role in healthcare.
-
Clearly, the second option is better for both countries.
What India Needs to Do
To protect its pharma sector, India must:
-
Continue talks with the US government and highlight the importance of generics.
-
Show how affordable medicines save lives and reduce healthcare costs worldwide.
-
Work with global associations to push for fair rules.
-
Reduce dependence on imported raw materials by boosting domestic API production.
-
Invest more in research and innovation to stay ahead in global markets.
Conclusion
The appeal from Indian drugmakers to leave generics out of the US import probe is about more than just business. It is about healthcare for millions of people. Generics make treatment affordable and accessible. Blocking them would harm patients in the US as well as damage India’s pharma industry.
India has built its reputation as both a strong monopoly medicine manufacturer and a trusted contract manufacturing hub. These strengths must not be overlooked during trade negotiations.
As global trade policies shift, one thing should remain constant—medicines must be affordable and accessible to all. For that reason, generic medicines must be kept out of restrictive trade actions.